SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
F O R M 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2025
TRINITY BIOTECH PLC
(Name of Registrant)
IDA Business Park
Bray, Co. Wicklow, Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form
40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279,
333-195232 and 333-253070).
EXPLANATORY NOTE
On August 14, 2025, the Company issued a press release announcing it had received regulatory approval to begin FDA-Cleared PreClara™
preeclampsia testing service. A copy of the press release is filed herewith as Exhibit 99.1.
EXHIBIT INDEX
|
Exhibit
|
|
Description
|
|
|
|
|
|
99.1
|
|
Trinity Biotech
Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
| |
TRINITY BIOTECH PLC
|
|
| |
|
Trinity Biotech plc
|
|
| |
|
(Registrant)
|
|
| |
|
|
|
| |
By:
|
/s/ John Gillard
|
|
| |
|
John Gillard
|
|
| |
|
Chief Executive Officer
|
|
Date: August 14, 2025
